Gastrointestinal Cancer

Successfully eliminating Helicobacter pylori from a patient’s gastrointestinal tract could lead to a significant decrease in gastric cancer risk.

Screening colonoscopy rates for colorectal cancer increased in low-income Latino populations when accompanied by patient navigation.

The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.

A quality improvement study indicated that nudges in the electronic health record were associated with a significant increase in clinician ordering of screening tests for breast and colorectal cancer.

A postsurgical circulating tumor DNA analysis after surgery and adjuvant chemotherapy may identify patients with stage III colorectal cancer at high risk of recurrence.

A rare occurrence, cancer in the esophagus requires an individualized treatment plan.

A multi-institutional pilot feasibility study looks at pencil beam scanning proton beam chemoradiation therapy with 5-fluorouracil and mitomycin-C for definitive treatment of carcinoma of the anal canal.   

A new study found artificial intelligence-based diagnostics could help with better diagnoses for upper gastrointestinal cancers.

Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy. 

Clinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.

An imaging-based biomarker may offer a way to personalize treatment for pancreatic ductal adenocarcinoma.

Previous laboratory research along with phase I and II trials suggested the combination of doxorubicin and sorafenib could offer improved outcomes in advanced hepatocellular cancer.

The U.S. Preventive Services Task Force released a new review of the benefits and harms of imaging-based screening for pancreatic cancer.

A combination of durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma.

Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas.

A new study found an upward trend over the last 12 years of cases of gastrointestinal cancer in young patients in Latin America.

In this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.

Dr. Wilson discusses a chemopreventive drug that may help prevent gastric cancer by acting directly on H. pylori.

This slideshow reviews the latest guidelines and updates on colorectal cancer screening.

Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma.

Data from the randomized OSLO-COMET trial were presented at ASCO 2019, revealing the survival of laparoscopic vs open surgery for liver metastases in colorectal cancer.

A longer progression-free survival with FOLFOXIRI plus bevacizumab was noted in patients with metastatic colorectal cancer with poor prognosis.

Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.

Researchers assessed outcomes with different chemo regimen doses in elderly or frail patients with gastroesophageal cancer, in this study presented ahead of the ASCO Annual Meeting.

Dr. Sinicrope reviews the phase III ATOMIC trial, which is testing standard chemotherapy alone or in combination with the anti–PD-L1 antibody atezolizumab as adjuvant therapy in a subset of colon cancer patients.

A study in JAMA evaluated whether adding high-dose vitamin D3 to standard chemotherapy improves PFS in patients with advanced or metastatic colorectal cancer.

A phase III trial examined immunotherapy in patients with microsatellite-stable metastatic colorectal cancer.

Researchers evaluated a “watch and wait” strategy that includes chemotherapy and radiation, but not surgery, in carefully selected patients with rectal cancer.

Investigators studied a combination of pertuzumab and trastuzumab in patients with metastatic, HER2-positive colorectal cancer.